Prognostication of astrocytoma patient survival by Ki-67 (MIB-1), PCNA, and S-phase fraction using archival paraffin-embedded samples
- PMID: 7884589
- DOI: 10.1002/path.1711740407
Prognostication of astrocytoma patient survival by Ki-67 (MIB-1), PCNA, and S-phase fraction using archival paraffin-embedded samples
Abstract
The prognostic power of three proliferation estimation methods, Ki-67 (MIB-1) and PCNA immunohistochemistry, and flow cytometry (S-phase and S + G2/M fractions, respectively), were evaluated in 50 cases of astrocytoma. Each proliferation index showed a strong association with the grade of malignancy (grades I-IV). The MIB-1 labelling index (LI) provided additional information, as it could be used for the discrimination of grade II and grade III astrocytomas (P = 0.0357). All three proliferation estimation methods also had strong prognostic potential (MIB-1 LI: P < 0.0001; PCNA Li: P < 0.0001; S-phase: P = 0.0004; S + G2/M: P = 0.0124). According to the receiver operating characteristics (ROC) curve, the MIB-1 LI showed generally the best sensitivity and specificity in placing the patients correctly into groups of survivors and non-survivors, which was further confirmed in the multivariate analysis. Only 4 per cent of the patients having high MIB-1 scores (> 15.3 per cent) were alive after 2-years' follow-up. In contrast, 72 per cent of patients with tumours of low proliferation activity survived. It appears that Ki-67 (MIB-1) immunolabelling using archival paraffin-embedded samples is of value in predicting prognosis in astrocytic tumours.
Similar articles
-
MIB-1 labeling index in astrocytic tumors--a clinicopathologic study.Clin Neuropathol. 2004 Nov-Dec;23(6):262-70. Clin Neuropathol. 2004. PMID: 15584210
-
Comparison of three quantitation methods for PCNA immunostaining: applicability and relation to survival in 83 astrocytic neoplasms.J Pathol. 1993 Nov;171(3):207-14. doi: 10.1002/path.1711710309. J Pathol. 1993. PMID: 7903983
-
Analysis of relative proliferation rates of Wilms' tumor components using proliferating cell nuclear antigen and MIB-1 (Ki-67 equivalent antigen) immunostaining and assessment of mitotic index.Lab Invest. 1994 Jan;70(1):125-9. Lab Invest. 1994. PMID: 7905542
-
Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value.Cancer. 2002 Apr 15;94(8):2151-9. doi: 10.1002/cncr.10458. Cancer. 2002. PMID: 12001111 Review.
-
Methodological aspects of using immunohistochemical cell proliferation biomarkers in colorectal carcinoma chemoprevention.J Cell Biochem Suppl. 1994;19:61-7. J Cell Biochem Suppl. 1994. PMID: 7823607 Review.
Cited by
-
Immunohistochemical Expression of Ki-67, PCNA and CD34 in Astrocytomas: A Clinicopathological Study.Oman Med J. 2012 Sep;27(5):368-74. doi: 10.5001/omj.2012.93. Oman Med J. 2012. PMID: 23074546 Free PMC article.
-
Ki-67 labeling is correlated with the time to recurrence in primary glioblastomas.J Neurooncol. 2002 Jan;56(2):127-32. doi: 10.1023/a:1014527929948. J Neurooncol. 2002. PMID: 11995813
-
Evaluation of brain tumor metabolism with [11C]choline PET and 1H-MRS.J Neurooncol. 2003 May;62(3):329-38. doi: 10.1023/a:1023342516925. J Neurooncol. 2003. PMID: 12777086
-
Prognostic value of tumour associated antigen immunoreactivity and apoptosis in cerebral glioblastomas: an analysis of 168 cases.J Clin Pathol. 1999 Aug;52(8):574-80. doi: 10.1136/jcp.52.8.574. J Clin Pathol. 1999. PMID: 10645226 Free PMC article.
-
MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor.Br J Cancer. 1997;75(9):1269-78. doi: 10.1038/bjc.1997.216. Br J Cancer. 1997. PMID: 9155045 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous